TheodoreScottNowickiMD
Pediatric Hematology & Oncology • Los Angeles, CAPediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology
Physician
Dr. Nowicki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 UCLA Medical Plz
Ste 265
Los Angeles, CA 90095Phone+1 310-825-0867Fax+1 310-206-4855
Summary
- Dr. Theodore Nowicki is a pediatric hematologist/oncologist in Los Angeles, CA and is affiliated with Ronald Reagan UCLA Medical Center. He received his medical degree from New York Medical College and has been in practice 4 years. He specializes in pediatric sarcoma oncology and pediatric solid tumor oncology.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 2016 - 2019- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 2013 - 2016
New York Medical CollegeClass of 2013
Certifications & Licensure
CA State Medical License 2014 - 2026- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer Start of enrollment: 2017 Jul 26
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma.Harvey K Chiu, Theodore S Nowicki, Masha J Livhits, James X Wu, Noah Federman
Journal of Pediatric Endocrinology & Metabolism. 2024-11-26 - Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis.Jack Pengfei Tang, Penelope Lafeuille, Alexandru Socolov, Sheila S Diamond, Jacob Aptekar
Cancer Research Communications. 2024-10-01 - 2 citationsInfusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy.Theodore S Nowicki, Cole W Peters, Crystal Quiros, Conner K Kidd, Moe Kawakami
Cancer Immunology Research. 2023-12-01
Journal Articles
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-cell PopulationsZeynep Eroglu, Iman Osman, Theodore S Nowicki, Antoni Ribas, Michael A Davies, Farbod Darvishian, Daniel Y Wang, Douglas B Johnson, Ravi K Amaravadi, Clinical Cancer Research
Press Mentions
- Low Blood Phosphate Levels May Be Linked to Neurological Side Effects from CAR T-cell TherapyOctober 19th, 2022
$4.6M CIRM Grant to Fund Phase 1 Trial of New Immunotherapy for Advanced Sarcoma, Difficult-to-Treat CancersMay 14th, 2019
$4.6 Million Grant Funds Clinical Trial of Stem Cell Immunotherapy for Metastatic Sarcoma and Other Hard-to-Treat CancersApril 30th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
